Final answer:
Compounds that inhibit NMDA receptors, such as CP-101,606 (Traxoprodil), can block LTP induction. These drugs are used to prevent the calcium influx that facilitates LTP, but their complete antagonism has side effects, so selective modulation of these receptors is preferred.
Step-by-step explanation:
To block LTP induction, a compound that could prevent the process is one which inhibits the function of NMDA receptors. Compounds such as antagonists to the NMDA or AMPA glutamate receptors can be effective in preventing the calcium influx that is critical to the LTP process. Specifically, drugs that target the NMDA receptor without overly suppressing its normal function, like CP-101,606 (Traxoprodil), have been used experimentally to moderate LTP and its effects, such as in cases of neurological diseases. However, due to side effects associated with complete antagonism of NMDA receptors, selective modulation is preferable to avoid disrupting the self-regulating mechanism of homeostatic plasticity. This selective approach attempts to curtail LTP-related excitotoxicity without causing adverse effects linked to general NMDA receptor antagonism.